

# Ahmed Idbaih

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/138765/ahmed-idbaih-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182  
papers

11,430  
citations

49  
h-index

104  
g-index

200  
ext. papers

14,050  
ext. citations

7.9  
avg, IF

5.72  
L-index

#	Paper	IF	Citations
182	Expression and prognostic value of CD80 and CD86 in the tumor microenvironment of newly diagnosed glioblastoma.. <i>Canadian Journal of Neurological Sciences</i> , <b>2022</b> , 1-22	1	0
181	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.. <i>European Journal of Cancer</i> , <b>2022</b> , 163, 98-107	7.5	
180	Hybrid [F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy.. <i>Clinical Neuroradiology</i> , <b>2022</b> , 1	2.7	1
179	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , <b>2022</b> ,	1	6
178	Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.. <i>Neuro-Oncology</i> , <b>2022</b> ,	1	8
177	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. <i>Neuro-Oncology</i> , <b>2021</b> , 23, vi55-vi56	1	3
176	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , <b>2021</b> , 3, e784-e794	14.4	6
175	Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. <i>Scientific Reports</i> , <b>2021</b> , 11, 10176	4.9	2
174	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1433-1446	1	6
173	Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1200-1202	1	2
172	Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 647	9.8	2
171	Sustained Tumor Control With MAPK Inhibition in V600-Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , <b>2021</b> , 97, e673-e683	6.5	4
170	IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 955-966	1	15
169	One-year survival of patients with high-grade glioma discharged alive from the intensive care unit. <i>Journal of Neurology</i> , <b>2021</b> , 268, 516-525	5.5	
168	Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters <b>2021</b> , 243-261		
167	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab078	0.9	1
166	Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab061	0.9	2

165	Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 162-168	7.5	3
164	Histiocytosis. <i>Lancet, The</i> , <b>2021</b> , 398, 157-170	40	13
163	Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 763	9.8	1
162	SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	2
161	Heterogeneity of Response to Iron-Based Metallo drugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
160	PAK3 is a key signature gene of the glioma proneural subtype and affects its proliferation, differentiation and growth. <i>Cellular Oncology (Dordrecht)</i> , <b>2021</b> , 44, 1257-1271	7.2	1
159	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 671972	5.3	4
158	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 130-146	7.5	22
157	5-Azacytidine in patients with IDH1/2-mutant recurrent glioma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 1226-1228	1	7
156	Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , <b>2020</b> , 196, 106006	2	3
155	Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading. <i>Oncogenesis</i> , <b>2020</b> , 9, 11	6.6	7
154	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , <b>2020</b> , 13,	6.6	33
153	Profiling Anti-Apoptotic BCL-xL Protein Expression in Glioblastoma Tumorspheres. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
152	Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. <i>ESMO Open</i> , <b>2020</b> , 5,	6	5
151	Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics. <i>Royal Society Open Science</i> , <b>2020</b> , 7, 191243	3.3	1
150	Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges. <i>Oncologist</i> , <b>2020</b> , 25, e1763-e1776	5.7	12
149	Central nervous system involvement in Erdheim-Chester disease: An observational cohort study. <i>Neurology</i> , <b>2020</b> , 95, e2746-e2754	6.5	3
148	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , <b>2020</b> , 580, 517-523	50.4	172

147	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2857-2865	2.2	68
146	Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 144, 33-41	4.8	29
145	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , <b>2019</b> , 92, e2754-e2763	6.5	6
144	Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3793-3801	12.9	127
143	Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations. <i>Oncologist</i> , <b>2019</b> , 24, 1584-1592 <sup>9</sup>	5.7	9
142	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. <i>Case Reports in Endocrinology</i> , <b>2019</b> , 2019, 2719364	1.2	1
141	CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1519-1528	1	45
140	The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 175	7.3	4
139	Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure. <i>Journal of Neurosurgery</i> , <b>2019</b> , 132, 875-883 <sup>3,2</sup>	3.2	16
138	Biodegraded magnetosomes with reduced size and heating power maintain a persistent activity against intracranial U87-Luc mouse GBM tumors. <i>Journal of Nanobiotechnology</i> , <b>2019</b> , 17, 126	9.4	12
137	Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 142, 139-148	4.8	3
136	Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 743-755	14.3	28
135	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 716-718	1	6
134	Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!. <i>Current Neurology and Neuroscience Reports</i> , <b>2018</b> , 18, 13	6.6	25
133	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E114-E117	7.1	53
132	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 495-504	13.4	86
131	ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 138, 479-486	4.8	30
130	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. <i>Oncologist</i> , <b>2018</b> , 23, 1500-1510	5.7	6

129	actionable mutations, molecular specificities, and outcome of adult midline gliomas. <i>Neurology</i> , <b>2018</b> , 90, e2086-e2094	6.5	29
128	Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma. <i>Neurology</i> , <b>2018</b> , 91, 523-525	6.5	14
127	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1170-1179	21.7	49
126	Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 267-283	14.3	12
125	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 608-617	4.5	28
124	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. <i>Acta Neuropathologica Communications</i> , <b>2018</b> , 6, 89	7.3	6
123	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e113-e125	21.7	124
122	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 691-703	14.3	78
121	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , <b>2017</b> , 49, 789-794	36.3	163
120	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , <b>2017</b> , 31, 347-358	3.1	10
119	Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience. <i>Journal of Neurology</i> , <b>2017</b> , 264, 2303-2312	5.5	7
118	Amplification and Mutations in Glioblastoma Patients of the Northeast of Morocco. <i>BioMed Research International</i> , <b>2017</b> , 2017, 8045859	3	9
117	Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma. <i>Theranostics</i> , <b>2017</b> , 7, 4618-4631	12.1	72
116	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 219-228	1	20
115	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1373-1385	21.7	518
114	Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field. <i>Journal of Controlled Release</i> , <b>2017</b> , 262, 259-272	11.7	40
113	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1954-1963	59.2	425
112	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , <b>2017</b> , 130, 1377-1380	2.2	95

111	Development of non-pyrogenic magnetosome minerals coated with poly-l-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia. <i>Biomaterials</i> , <b>2017</b> , 141, 210-222	15.6	54
110	Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 729-731	1.9	1
109	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. <i>Brain Pathology</i> , <b>2017</b> , 27, 567-579	6	13
108	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 2306-2316	27.4	875
107	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 388-400	1	102
106	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , <b>2016</b> , 132, 625-34	14.3	72
105	Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and IDH-Mutated Gliomas. <i>Oncologist</i> , <b>2016</b> , 21, 1131-5	5.7	8
104	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. <i>Nature Communications</i> , <b>2016</b> , 7, 11263	17.4	55
103	Clinical trial of blood-brain barrier disruption by pulsed ultrasound. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 343re2	17.5	377
102	Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. <i>Expert Review of Neurotherapeutics</i> , <b>2016</b> , 16, 1285-1300	4.3	54
101	Basal Ganglia Germinoma in an Adult. <i>World Neurosurgery</i> , <b>2016</b> , 92, 584.e11-584.e14	2.1	2
100	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1185-96	12.9	54
99	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , <b>2016</b> , 7, 21556-69	3.3	19
98	Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 888-90	1	12
97	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 1161-1167	44.5	68
96	Precision medicine in glioblastoma therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2016</b> , 1, 451-468	1.6	
95	Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 122, 273-81	4.8	12
94	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 955-62	3.5	15

93	Dural Arteriovenous Fistula Mimicking a Brainstem Glioma. <i>Journal of Neuroimaging</i> , <b>2015</b> , 25, 1053-5	2.8	10
92	Emerging circulating biomarkers in glioblastoma: promises and challenges. <i>Expert Review of Molecular Diagnostics</i> , <b>2015</b> , 15, 1311-23	3.8	45
91	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , <b>2015</b> , 85, 1325-31	6.5	25
90	Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 124, 385-92	4.8	5
89	Clinical Spectrum of Encephalitis Associated With Antibodies Against the $\alpha$ Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1163-9	17.2	91
88	TCF12 is mutated in anaplastic oligodendroglioma. <i>Nature Communications</i> , <b>2015</b> , 6, 7207	17.4	32
87	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. <i>Cancer Cell</i> , <b>2015</b> , 28, 307-317	24.3	176
86	Quantifying the heritability of glioma using genome-wide complex trait analysis. <i>Scientific Reports</i> , <b>2015</b> , 5, 17267	4.9	25
85	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 2535-43	27.4	696
84	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. <i>CNS Oncology</i> , <b>2015</b> , 4, 381-6	4	10
83	Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 411-8	2.2	186
82	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3307-17	12.9	176
81	TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 118, 131-9	4.8	25
80	Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. <i>Cancer</i> , <b>2014</b> , 120, 3972-80	6.4	51
79	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 883-93	3.8	13
78	The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1537-43	5.5	9
77	DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide. <i>PLoS ONE</i> , <b>2014</b> , 9, e104455	3.7	14
76	Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. <i>Genome Biology</i> , <b>2014</b> , 15, 471	18.3	26

75	Tumor and endothelial cell hybrids participate in glioblastoma vasculature. <i>BioMed Research International</i> , <b>2014</b> , 2014, 827327	3	14
74	An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. <i>BioMed Research International</i> , <b>2014</b> , 2014, 282815	3	6
73	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1244-54	1	35
72	Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , <b>2014</b> , 83, 1478-80	6.5	47
71	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 662-70	1	55
70	Molecular analysis of diffuse intrinsic brainstem gliomas in adults. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 116, 405-11	4.8	59
69	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 400-8	1	7
68	A novel tumor suppressor function of Kindlin-3 in solid cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 8970-85	3.3	25
67	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 328-36	2.2	80
66	Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas. <i>Cancer</i> , <b>2013</b> , 119, 806-13	6.4	19
65	Neuro-oncology: Novel molecular targets in treatment of glioblastoma. <i>Nature Reviews Neurology</i> , <b>2013</b> , 9, 612-3	15	3
64	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5513-22	12.9	89
63	Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 542-7	1	40
62	Deciphering the 8q24.21 association for glioma. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 2293-302	5.6	45
61	Prophylactic intrathecal chemotherapy in primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 143-6	4.8	39
60	Primary brain tumours in adults. <i>Lancet, The</i> , <b>2012</b> , 379, 1984-96	40	447
59	Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. <i>Neuro-Oncology</i> , <b>2012</b> , 14, 1393-403	1	31
58	DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. <i>PLoS ONE</i> , <b>2012</b> , 7, e38881	3.7	24



57	SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. <i>PLoS ONE</i> , <b>2012</b> , 7, e45950	3.7	23
56	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , <b>2012</b> , 60, 885-94	7.3	38
55	Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors. <i>Expert Review of Molecular Diagnostics</i> , <b>2012</b> , 12, 265-77	3.8	1
54	Oligodendrogliomas: new insights from the genetics and perspectives. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 687-93	4.2	21
53	A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5071-80	12.9	84
52	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5203-11	12.9	170
51	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 802-8	7.5	33
50	Chromosome 7p11.2 (EGFR) variation influences glioma risk. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 2897-904	9.4	129
49	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. <i>Orphanet Journal of Rare Diseases</i> , <b>2011</b> , 6, 83	4.2	39
48	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 781-9	3.5	49
47	Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 101, 457-62	4.8	22
46	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 103, 221-30	4.8	18
45	Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 105, 219-24	4.8	35
44	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. <i>Cancer</i> , <b>2011</b> , 117, 3014-26	6.4	26
43	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 84-98	1	99
42	A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7148-55	12.9	93
41	Progress récents dans la génomique et dans le traitement médical des gliomes cérébraux. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2011</b> , 195, 11-21	0.1	1
40	Array-based genomics in glioma research. <i>Brain Pathology</i> , <b>2010</b> , 20, 28-38	6	12

39	Prognostic markers in gliomas. <i>Future Oncology</i> , <b>2010</b> , 6, 733-9	3.6	15
38	Genetic risk profiles identify different molecular etiologies for glioma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5252-9	12.9	48
37	IDH1 gene mutations: a new paradigm in glioma prognosis and therapy?. <i>Oncologist</i> , <b>2010</b> , 15, 196-9	5.7	43
36	Mutation des gènes IDH1/IDH2 : un nouveau marqueur pronostique dans les gliomes. <i>Revue Neurologique</i> , <b>2010</b> , 166, S22-S23	3	1
35	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , <b>2010</b> , 9, 234	42.1	34
34	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1597-604	12.9	328
33	A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. <i>Brain</i> , <b>2010</b> , 133, 973-82	11.2	271
32	Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 97, 353-64	4.8	22
31	Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 100, 439-41	4.8	13
30	ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. <i>Cancer Cell International</i> , <b>2010</b> , 10, 1	6.4	64
29	NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. <i>PLoS ONE</i> , <b>2009</b> , 4, e4107	3.7	15
28	CRX is a diagnostic marker of retinal and pineal lineage tumors. <i>PLoS ONE</i> , <b>2009</b> , 4, e7932	3.7	35
27	TP53 mutations but no CHEK2 *1100DelC variant in familial gliomas. <i>Cancer Genetics and Cytogenetics</i> , <b>2009</b> , 188, 126-8		3
26	Genome-wide association study identifies five susceptibility loci for glioma. <i>Nature Genetics</i> , <b>2009</b> , 41, 899-904	36.3	640
25	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4150-4	2.2	752
24	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 537-42	4.2	38
23	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. <i>Neuropathology</i> , <b>2008</b> , 28, 440-3	2	19
22	Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. <i>Brain Research</i> , <b>2008</b> , 1198, 16-20	3.7	10

21	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. <i>Molecular Cancer</i> , <b>2008</b> , 7, 41	42.1	127
20	Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , <b>2008</b> , 10, 540-7	1	26
19	Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. <i>Oncologist</i> , <b>2008</b> , 13, 978-92	5.7	38
18	BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 1778-86	7.5	90
17	Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 87, 181-7	4.8	59
16	Mutational analysis of Rac2 in gliomas. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 87, 365-6	4.8	2
15	Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 88, 185-8	4.8	9
14	Genomic changes in progression of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , <b>2008</b> , 90, 133-40	4.8	43
13	18F-FDG PET in neurodegenerative Langerhans cell histiocytosis : results and potential interest for an early diagnosis of the disease. <i>Journal of Neurology</i> , <b>2008</b> , 255, 575-80	5.5	23
12	Altered cerebral glucose metabolism in an animal model of diabetes insipidus: a micro-PET study. <i>Brain Research</i> , <b>2007</b> , 1158, 164-8	3.7	7
11	Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. <i>Cancer Genetics and Cytogenetics</i> , <b>2007</b> , 176, 121-6		14
10	TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. <i>Cancer Genetics and Cytogenetics</i> , <b>2007</b> , 177, 103-7		14
9	No association of MDM2 SNP309 with risk of glioblastoma and prognosis. <i>Journal of Neuro-Oncology</i> , <b>2007</b> , 85, 241-4	4.8	13
8	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , <b>2007</b> , 19, 606-11	4.2	48
7	Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 2182-92	6.1	45
6	MRI of clot in cerebral venous thrombosis: high diagnostic value of susceptibility-weighted images. <i>Stroke</i> , <b>2006</b> , 37, 991-5	6.7	188
5	Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. <i>Laboratory Investigation</i> , <b>2005</b> , 85, 176-81	5.9	68
4	Two types of chromosome 1p losses with opposite significance in gliomas. <i>Annals of Neurology</i> , <b>2005</b> , 58, 483-7	9.4	138

3	Clinical course and MRI changes of basilar artery dolichoectasia: three case reports. <i>Cerebrovascular Diseases</i> , <b>2004</b> , 17, 262-4	3.2	6
2	Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. <i>Pediatric Blood and Cancer</i> , <b>2004</b> , 43, 55-8	3	48
1	Robust methylation-based classification of brain tumors using nanopore sequencing		1